Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2010

View Archived Issues

Pharmaxis acquires Topigen and issues 3.2 million shares

Dainippon Sumitomo Pharma offers quarterly update

Insight into the mechanistic and molecular basis of entecavir resistance in HBV

Lung Rx and ImmuneWorks sign development agreement for IW-001 in IPF and PGD

Synergistic antitumor effects of tumor-targeted superantigen combined with anti-CTLA-4

Merck & Co. discloses novel HIV integrase inhibitors

New PAI-1 inhibitors identified by Kowa

Novel neuroprotective agent Indip shows promise in stroke model

Vitae Pharmaceuticals identifies new renin inhibitors

MAP initiates PK study of Levadex in smokers and nonsmokers

TopoTarget discloses novel NMPRTase inhibitors

Tyrosine kinase inhibitors for cancer therapy disclosed by Merck KGaA

Embera and Exponential sign clinical development agreement for EMB-001C

U.K. MHRA approves Oncolytics' phase III trial of Reolysin in head and neck cancers

Quark granted orphan drug designation for QPI-1002 in DGF in kidney transplants

FDA approves REMS for erythropoiesis-stimulating agents

Prezista approved for pediatric use in Canada

Athersys completes enrollment in phase I trial of stem cell therapy MultiStem in AMI

ImmuneRegen and Fred Hutchinson Cancer Research Center to initiate homspera trials

PARI Pharma begins enrollment in phase IIb L-CsA trial in bronchiolitis obliterans

Alkermes reports phase I results of ALKS-37 in opioid-induced constipation

Novel selective and orally active inhibitors of PKB show potent antitumor effects in vivo

ERYtech and M.D. Anderson Cancer Center to develop biomarker assay for personalized treatment

Wyeth discloses the discovery of novel PARP-1 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...